Two Guys One Ticker analyzes Definium Therapeutics ahead of Q3 earnings, outlining base, bear, and bull cases for DFTX.
Summary
Preston Hayes and Logan Pierce discuss Definium Therapeutics (DFTX) ahead of its Q3 earnings report on November 9, 2026. They highlight the company's recent stock performance, noting a 148% year-to-date gain despite a recent pullback from highs. The hosts review three positive Phase 3 clinical readouts for the lead asset DT120ODT in anxiety and depression, alongside Breakthrough Therapy Designations from the FDA. They outline a base case of steady regulatory progress, a bear case citing FDA and scheduling risks, and a bull case focused on the massive market opportunity for a first-approved psychedelic treatment. The episode concludes with an overview of analyst consensus, which rates all 19 covering analysts as buy with a consensus price target of $72.56.
Key takeaways
- 1 DT120 holds Breakthrough Therapy Designation for generalized anxiety disorder (granted March 2024) and major depressive disorder (granted September 2026).
Logan Pierce · 3:57
- 2 There are 19 analysts covering the stock, all rated buy, with a consensus price target of $72.56, a low of $55, and a high of $91.
Logan Pierce · 10:25
Episode sections
- 0:00 – 0:47
Episode Introduction and Context
Preston Hayes and Logan Pierce introduce the episode as a setup for Definium Therapeutics (DFTX) ahead of its Q3 earnings report on Monday, November 9. They note that as a pre-revenue biotech, the stock moves on clinical data, cash, and FDA progress rather than traditional earnings metrics.
- 0:47 – 1:49
Stock Price Performance and Market Cap
The speakers detail DFTX's recent price action, noting a close of $33.27 on November 6, up 9.6% intraday but down 8.4% over five days and 28% over three months. Despite recent declines, the stock is up 148% year-to-date with a market cap of roughly $4.5 billion and a beta of 2.38.
- 1:49 – 2:28
Company Overview and Lead Asset DT120
Definium Therapeutics, formerly Mind Medicine (MindMed), is a late-stage clinical biopharmaceutical company. Its lead drug, DT120ODT, is an orally disintegrating tablet containing Lysergide (LSD), administered as a single 100-microgram dose under supervision for anxiety, depression, and PTSD.
- 2:28 – 3:57
Phase 3 Clinical Readouts
The company reported three positive Phase 3 readouts in 2026: one in major depressive disorder (June), one in generalized anxiety disorder called Voyage (August), and a second anxiety study called Panorama (September). The speakers highlight the statistical significance and effect sizes of these trials.
- 3:57 – 5:24
Regulatory Status and Timeline
DT120 holds Breakthrough Therapy Designation for both generalized anxiety disorder (granted March 2024) and major depressive disorder (granted September 2026). Definium expects a pre-NDA meeting with the FDA in Q4 2026 and anticipates filing the New Drug Application in the first half of 2027.
- 5:24 – 7:33
Q3 Earnings Expectations and Cash Position
Consensus expects a loss of $0.55-$0.56 per share with zero revenue, a significant improvement from the $0.78 loss in the prior year quarter. The company holds approximately $1.1 billion in cash, extending its operating runway into 2030, following an $805 million public offering.
- 7:33 – 10:25
Base, Bear, and Bull Cases
The base case assumes a non-event earnings report with steady regulatory progress. The bear case highlights risks such as FDA pushback, lack of revenue diversification, controlled substance scheduling hurdles, and potential dilution. The bull case focuses on the massive market opportunity for a first-approved psychedelic treatment and strong analyst consensus.
- 10:25 – 13:39
Analyst Ratings and Price Targets
All 19 covering analysts rate the stock a buy with a consensus target of $72.56. Recent targets include Bank of America at $91, J.P. Morgan at $84, and others ranging from $66 to $79. The speakers caution that many targets were set before the recent stock price decline.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX | equity | neutral | That is the setup. Definium Therapeutics, DFTX, reports Monday, November 9th, after the close, call at 4.30pm Eastern. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Definium reports third quarter results after the market close on Monday, November 9, with a conference call at 4:30 p.m. Eastern.
Preston Hayes ·0:14
How to verify: Check Definium Therapeutics investor relations page or SEC filings for the Q3 earnings release date and time. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
Primary sourceDFTX closed Friday, November 6th at $33.27, up $2.91 on the day, about 9.6% from a prior close of $30.36.
Preston Hayes ·0:47
How to verify: Check historical stock price data for DFTX on November 6, 2026, via financial data providers like Bloomberg or Yahoo Finance. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
Primary sourceThe stock is down about 8.4% over the last 5 days, down about 28% over 3 months, and down about a third from its 52-week high of $49.70.
Logan Pierce ·1:09
How to verify: Calculate price changes for DFTX over the specified periods using historical stock data. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
The 52-week low is about $10.47.
Logan Pierce ·1:09
How to verify: Check 52-week low data for DFTX on financial data providers. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
The stock is up about 148% year-to-date and about 184% over the last year.
Preston Hayes ·1:28
How to verify: Calculate YTD and 1-year returns for DFTX using historical stock data. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
The market cap is roughly $4.5 billion.
Preston Hayes ·1:35
How to verify: Check current market capitalization for DFTX on financial data providers. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
Beta is about 2.38.
Preston Hayes ·1:35
How to verify: Check beta data for DFTX on financial data providers. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
Definium is a late-stage clinical biopharmaceutical company, formerly known as Mind Medicine, or MindMed.
Logan Pierce ·1:49
How to verify: Check Definium Therapeutics corporate history on its investor relations page or SEC filings. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
Primary sourceIts lead drug is DT120ODT, an orally disintegrating tablet form of Lysergide, which is LSD.
Logan Pierce ·1:49
How to verify: Check Definium Therapeutics pipeline information on its investor relations page or clinical trial registries. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
One single dose, 100 micrograms, taken under supervision.
Logan Pierce ·2:05
How to verify: Check clinical trial protocols or press releases for DT120 dosing regimen. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.
Do your own research
- Verify Q3 earnings results and cash position in Definium Therapeutics' 8-K filing or earnings press release due November 9, 2026.
- Review the full clinical data and statistical significance from the Voyage and Panorama Phase 3 trial results published in medical journals or company presentations.
- Check the FDA's official database for the status of Breakthrough Therapy Designations and the schedule of Lysergide (LSD) under the Controlled Substances Act.
- Compare the current stock price and market cap against the consensus analyst price targets of $72.56 to assess valuation premiums.
- Investigate the company's cash burn rate and dilution risks given the $805 million public offering and runway into 2030.
- Read the latest analyst reports from Bank of America ($91 target) and J.P. Morgan ($84 target) to understand the assumptions behind their bullish ratings.
- Confirm the timeline for the pre-NDA meeting with the FDA expected in Q4 2026 and the anticipated NDA filing in the first half of 2027.
Full transcriptexpand
- 0:00
- Preston Hayes: Welcome back to Two Guys, One Ticker. I am Preston Hayes.
- 0:04
- Logan Pierce: And I am Logan Pierce. Today we are doing Definium Therapeutics, ticker DFTX, and we are doing it before the news because the news lands Monday.
- 0:14
- Preston Hayes: Right. Definium reports third quarter results after the market closes on Monday, November 9th, with a conference call at 4.30 p.m. Eastern.
- 0:22
- Preston Hayes: So this is the setup episode. What is the company? What should you actually listen for on that? call? And what are the base, bear, and bull cases going into it?
- 0:31
- Logan Pierce: And the first thing to get straight is that this is not a normal earnings episode. Definium is a pre-revenue biotech. There is no revenue line to beat or miss. The stock moves on clinical data, cash, and the road to the FDA. Monday is a check check-in in on all three.
- 0:47
- Preston Hayes: Let us start with where the stock sits. DFTX closed. Friday, November 6th at $33.27, up $2.91 on the day, about 9.6% from a prior close of $30.36. The intraday range Friday was about $30.91 to $33.42.
- 1:09
- Logan Pierce: That Friday bounce is real, but zoom out and the picture is messier. The stock is down about 8.4%. 8.4% over the last 5 days even after that bounce, down about 28% over 3 months, and down about a third from its 52-week high of $49.70. The 52-week low is about $10.47.
- 1:28
- Preston Hayes: And yet it is still up about 148% year-to-date and about 184% over the last year.
- 1:33
- Preston Hayes: The
- 1:35
- Preston Hayes: Market cap is roughly $4.5 billion. billion. Beta is about 2.38, which is a polite way of saying this thing moves about twice as fast as the market, in both directions.
- 1:46
- Logan Pierce: So what does Definium actually do?
- 1:49
- Logan Pierce: It is a late-stage clinical biopharmaceutical company, formerly known as Mind Medicine, or MindMed. Its lead drug is DT120ODT, an orally disintegrating tablet form formed of Lysergyde, which is LSD.
- 2:05
- Logan Pierce: One single dose, 100 micrograms, taken under supervision.
- 2:10
- Preston Hayes: And the indications are big ones. Generalized anxiety disorder, major depressive disorder, and eventually post-traumatic stress disorder.
- 2:18
- Preston Hayes: No psychedelic compound currently holds FDA approval for anxiety The or depression. So if this works, it is not a small niche. it is a new
- 2:28
- Logan Pierce: clinical story in 2026 has been genuinely strong, and that is not hype. That is three positive Phase 3 readouts. Let us walk through them, because Monday's call will be framed by them.
- 2:39
- Preston Hayes: first emerge in major depressive disorder reported in june 2026
- 2:44
- Preston Hayes: solid then voyage in generalized anxiety disorder reported in august 2026 plus a single one
- 2:49
- Preston Hayes: PLUS A SINGLE 100 MICROGRAM DOSE PRODUCED A PLACEBO ADJUSTED REDUCTION OF 5.4 POINTS ON THE HAMILTON ANXIETY RATING SCALE WITH A COHEN'S D OF 0.81
- 3:01
- Preston Hayes: AND THAT IS A LARGE EFFECT SIZE FOR PSYCHIATRY
- 3:04
- Logan Pierce: Then Panorama, the second Phase 3 study in anxiety, reported September 14, 2026.
- 3:10
- Logan Pierce: This one matters because it is the replication. Panorama enrolled 240 245 adults with generalized anxiety disorder across about 32 sites.
- 3:19
- Logan Pierce: The 100-microgram dose produced a Hamilton anxiety score change of –9.8 vs. –4.7 for placebo,
- 3:26
- Logan Pierce: a placebo-adjusted difference of 5.1 points, with a p-value under 0.0001 and a Cohen's d of 0.64.
- 3:36
- Preston Hayes: So the effect size in Panorama, 0.64,
- 3:39
- Preston Hayes: is a bit below Voyage at 0.81,
- 3:42
- Preston Hayes: but it is still a strong result, and critically, it is the second positive anxiety study, three positive Phase III readouts in total, and the effect showed up fast, with differences visible as early as Day 2 and sustained through Week 12.
- 3:57
- Logan Pierce: The FDA has noticed. DT120 already had breakthrough therapy designation for generalized anxiety disorder, granted back in March 2024, and in September 2026, the FDA granted a second breakthrough therapy designation for major depressive disorder. Breakthrough therapy is not approval, let us be clear, but it
- 4:17
- Logan Pierce: means enhanced agency guidance and a faster lane for development and review.
- 4:22
- Preston Hayes: and the regulatory calendar is the real story here. Definium says it expects a pre-NDA meeting with the FDA in the fourth quarter of 2026,
- 4:30
- Preston Hayes: so basically right now, and it anticipates filing the new drug application in the first half of 2027. That is the path from clinical data to an actual drug on the market.
- 4:45
- Logan Pierce: The company is still ongoing and is expected to read out in 2027, and the company plans to start a Phase 3 trial in PTSD in 2027. So the pipeline after the anxiety filing is depression replication, then PTSD.
- 5:00
- Preston Hayes: The company has also been out presenting the data. At the NEI Fall Congress this week, November 4-7,
- 5:06
- Preston Hayes: Definium presented top-line Phase III data for DT120 in both anxiety and depression, including the first Congress presentation of Panorama.
- 5:15
- Preston Hayes: SO THE MEDICAL COMMUNITY IS SEEING THIS IN DETAIL NOW, NOT JUST IN PRESS RELEASES.
- 5:20
- Logan Pierce: OKAY, NOW MONDAY, WHAT ARE THE NUMBERS EXPECTED TO BE?
- 5:24
- Logan Pierce: CONSENSUS IS A LOSS OF ABOUT 55 TO 56 CENTS PER SHARE, WITH REVENUE EXPECTED TO REMAIN AT ZERO. FOR COMPARISON, THE LOSS IN THE SAME QUARTER LAST YEAR WAS ABOUT 78 In CENTS PER SHARE.
- 5:36
- Preston Hayes: AND THE OPTIONS MARKET IS PRICING A BIG MOVE, ABOUT plus or minus 13-14% around the report. That is a lot for a stock that, according to one tracker, has averaged only about a 2% move over its last 8 earnings reports. The market is saying this one is different, probably because the stock has already moved so much and the regulatory clock is ticking.
- 5:56
- Logan Pierce: Here's the thing I'm to starting remember about the last report, because it explains why the headline number on Monday could mislead you. In the second quarter, reported August 6, Definium posted a loss of $1.44 per share, against a consensus of about $0.54. That looks like a huge miss, but it was driven largely by a non-cash warrant liability charge.
- 6:16
- Logan Pierce: The operating story and the accounting story were not the same thing.
- 6:20
- Preston Hayes: so on monday Someday, do not just read the eps headline listen for cash burn and runway as of june 30th, Definium had about $1.1 billion in cash, cash equivalents, and investments, after an $805 million public offering. The company has said that extends its operating runway into 2030.
- 6:40
- Logan Pierce: That cash position is a genuine differentiator. A lot of small cap biotechs live quarter to The other quarter thing to raising listen for money is at the pre-NDA bad meeting prices. itself. Is Definium, it scheduled? Has it happened? after What that did raise, the FDA does say about not the have filing that package? problem right now.
- 7:07
- Preston Hayes: The company has said the meeting is in the fourth quarter. Any color on timing or on what the FDA wants to see in the NDA will matter more than any earnings prediction. per share number.
- 7:16
- Logan Pierce: Same with Ascend Enrollment and any update on commercial preparation. If you are filing in the first half of 2027, you need to be building the commercial machine now.
- 7:25
- Logan Pierce: Supervised dosing, clinic logistics, controlled substance handling, reimbursement, that is not a trivial launch.
- 7:33
- Preston Hayes: Let us do the cases. Base case first. The base case is that Monday is a non-event on the numbers. A small loss, zero revenue, cash still around a billion. And the call is steady on the regulatory path. The pre-NDA meeting is on track. The NDA filing is still first half of 2027. Ascend is enrolling. And nothing
- 7:53
- Preston Hayes: changes the story.
- 7:54
- Logan Pierce: In that base case, the stock probably trades on The the bear broader case is where market you have and to on be honest positioning about what into the this filing, company is. not It is on a single Monday asset itself. company. The DT120 three is the Phase story. If 3 the readouts FDA pushes back, are if the already NDA filing slips, if the agency wants more data, there is no second drug to fall back on, no revenue to cushion it.
- 8:21
- Preston Hayes: If the agency wants more data, there is no second drug to fall back on, no revenue to cushion it.
- 8:27
- Logan Pierce: And the regulatory risk is real, even with breakthrough therapy designation. Top line results are sponsor communications, not peer-reviewed publications yet. The FDA will look at the full data, safety in detail, and the practical questions. How does a supervised single-dose LSD treatment actually work in the real world? Who administers it, where,
- 8:47
- Logan Pierce: and how is it paid for?
- 8:49
- Preston Hayes: Plus the controlled substance issue. Lysergide is a Schedule I controlled substance under federal law. Even if the FDA approves the drug, the DEA scheduling process, the clinic infrastructure, and the stigma around psychedelics are all real commercial hurdles. Approval is not the same as a successful launch.
- 9:07
- Logan Pierce: The financial bear case is simpler. No New revenue, ongoing losses, and a stock that has already run 148% this year. The trailing 12 months this of the year has year. been a big
- 9:13
- Unidentified speaker (UNKNOWN): one for
- 9:14
- Logan Pierce: The the stock trailing market. 12-month net loss is about $354 million. If the market gets risk-averse, and we just saw a week ago how fast that can happen in the AI trade, a high-beta, pre-revenue biotech is exactly the kind of stock that gets sold first.
- 9:29
- Preston Hayes: and there is dilution history to remember
- 9:31
- Preston Hayes: the 805 million dollar offering that built This the cash pile also added shares that is the right is trade for a biotech cash for
- 9:40
- Preston Hayes: a reminder that the share count grows when the company needs money.
- 9:43
- Logan Pierce: Now the bull case, and it is a real one. Three positive Phase 3 readouts, two in anxiety, one in depression, with effect sizes that are large by psychiatry standards. A drug that works after a single dose with The market effects opportunity visible is by enormous. day Anxiety two in and depression disorders are among where the current largest psychiatric treatments markets take in the weeks world, and and often there has do not not been work a truly well enough new mechanism
- 10:03
- Logan Pierce: in decades.
- 10:15
- Preston Hayes: If DT120 becomes the first approved psychedelic-derived treatment for anxiety and depression, the peak sales conversation is in the billions, not the hundreds of millions.
- 10:25
- Logan Pierce: And the street is, frankly, all in. 19 analysts cover the stock, all 19 rated a buy, zero holds, zero sells, with a consensus strong buy rating. The average price target is about $72.56 against a current price around $33, with a low target of $55 and a high of $91.
- 10:45
- Preston Hayes: Let us name a few of those because they are recent. Bank of America maintained a buy with a $91 target in early October. J.P. Morgan initiated coverage with an overweight rating and an $84 target on October 9th.
- 10:59
- Preston Hayes: Adbird raised its target to $79 in mid-September.
- 11:03
- Preston Hayes: Canaccord raised to $78.
- 11:05
- Preston Hayes: RBC is at $66.
- 11:08
- Logan Pierce: But here is the caveat, and we have to say it because it is the same caveat we gave on AMD last week. most of those targets were set or reiterated in mid-September and early October before the stock slid from around $38 to around $32. The average target implies more than 100% upside, but part of that is stale targets meeting a lower
- 11:28
- Logan Pierce: price. Watch for revisions around the next catalyst.
- 11:31
- Preston Hayes: The other bullet point is the cash. $1.1 billion, DOLLARS, runway into 2030, no near-term financing overhang? THAT MEANS THE COMPANY CAN GET THROUGH THE NDA FILING, THE FDA REVIEW, AND INTO LAUNCH PREPARATION WITHOUT GOING BACK TO THE MARKET CAP IN HAND. FOR BIOTECH, THAT IS FREEDOM.
- 11:57
- Logan Pierce: PTSD STARTING PHASE 3 IN 2027 OPENS A THIRD INDICATION IF THE ANXIETY NDA GOES WELL, THE STORY DOES NOT END THERE, IT EXPANDS.
- 12:21
- Preston Hayes: 3. ASCEND ENROLLMENT AND TIMING 4. ANY COMMERCIAL PREPARATION COLOR, CLINICS, DISTRIBUTION, REIMBURSEMENT
- 12:30
- Preston Hayes: 5. THE EPS HEADLINE, BUT ONLY AFTER STRIPPING OUT NON-CASH ITEMS LIKE THE WARRANT CHARGE THAT DISTORTED LAST QUARTER
- 12:38
- Logan Pierce: And the meta point, this is a pre-earnings episode for a company where earnings are not the event. The event is the FDA NDA path. Monday is a chance to hear management's tone on that path right before the pre-NDA meeting window. CLOSES. IF THEY SOUND CONFIDENT AND SPECIFIC, THAT MATTERS. IF THEY SOUND VAGUE OR PUSH TIMELINES, THAT MATTERS
- 12:58
- Logan Pierce: MORE.
- 13:09
- Preston Hayes: The real move comes later, on the FDA meeting readout and the filing.
- 13:17
- Logan Pierce: That is the setup. Definium Therapeutics, DFTX, reports Monday, November 9th, after the close, call at 4.30pm Eastern.
- 13:26
- Logan Pierce: We will do the post-earnings follow-up after we hear what they actually said.
- 13:30
- Preston Hayes: I am Preston Hayes.
- 13:32
- Logan Pierce: And I am Logan Pierce. This is Two Guys, One Ticker. We will see you after the print.